Home > Insider Trading > Filing (0001209191-23-026683)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1598646	Minerva Neurosciences Inc.	NERV	Pharmaceutical Preparations (2834)	260784194

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610384	Remy Luthringer	C/O Minerva Neurosciences, Inc. 1500 District Avenue Burlington MA 01803	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-04-28	88,077	$0.00	96,388	No	4	A	Direct
Common Stock	Disposition	2023-05-01	23,753	$3.85	72,635	No	4	S	Direct
Common Stock	Disposition	2023-05-02	3,641	$3.76	68,994	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	115,825	Indirect	By Wint2felden Holding SA

Footnotes

Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs"), representing 50% of the shares underlying the PRSUs. On April 28, 2023, the Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for roluperidone.
The sales reported in this Form 4 represent nondiscretionary sales of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of the PRSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.90 inclusive.